Compound Sodium Lactate Solution for Infusion BP
*Company:
Baxter Holding B.V.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 23 April 2024
File name
ie_spc_Compound-Sodium-Lactate_PA2299-012-001_June 2023.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 August 2023
File name
CSL - PIL TH-30-02-118_LABEL Sept 2021.pdf
Reasons for updating
- New PIL for new product
Updated on 23 January 2023
File name
ie-spc-2019-03-compound-sodium-lactate-PA2299012001.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 04 April 2019
File name
ie-spc-2019-03-compound-sodium-lactate-PA2299012001.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 11 May 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 11 May 2017
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8 update to Adverse Reporting paragraph.
Section 6.3 change in shelf life for 250 ml container
Section 6.4 Change to storage information
Updated on 11 May 2017
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 4.8 update to Adverse Reporting paragraph.
Section 6.3 change in shelf life for 250 ml container
Section 6.4 Change to storage information
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Free text change information supplied by the pharmaceutical company
Baxter Holding B.V.
Address:
Kobaltweg 49, 3542CE Utrecht, NetherlandsMedical Information E-mail:
medinfo_uki@baxter.comTelephone:
+44 (0)1635 206 345Medical Information Facsimile:
+44 (0)1635 206071Medical Information Direct Line:
+44 (0)1635 206345